Conduit Pharmaceuticals (CDT) announces the filing of a new composition of matter patent covering a novel solid form of AZD5904, a clinical-stage myeloperoxidase, MPO, inhibitor in the Company’s pipeline. This novel solid form offers significantly enhanced solubility relative to previously studied forms of AZD5904. This improved solubility enables new formulations that were previously not feasible, better aligning the compound’s pharmacokinetics with targeted disease biology and patient needs. The filing represents a significant development for AZD5904, which previously had limited intellectual property coverage restricted to its use in idiopathic male infertility. This composition of matter patent now positions Conduit to potentially secure a new intellectual property runway for the asset of up to 20 years, enabling a renewed strategic focus on broader clinical development opportunities.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDT:
- Conduit Pharmaceuticals Approves Reverse Stock Split Amendments
- Conduit Pharmaceuticals files to sell 2.2M shares of common stock for holders
- Conduit Pharmaceuticals announces Regan appointed as CEO
- Biotech Alert: Searches spiking for these stocks today
- Conduit Pharmaceuticals announces novel cocrystal patent filing for VTAMA
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue